Merck & Company, Inc. (MRK) Position Raised by Utah Retirement Systems

Merck & Company, Inc. (MRK) Position Raised by Utah Retirement Systems

Utah Retirement Systems raised its position in shares of Merck & Company, Inc. (NYSE:MRK) by 0.0% during the third quarter, according to its most recent Form 13F filing with the SEC. The fund owned 507,710 shares of the company’s stock after buying an additional 100 shares during the period. Merck & Company comprises 0.8% of Utah Retirement Systems’ investment portfolio, making the stock its 19th largest position. Utah Retirement Systems’ holdings in Merck & Company were worth $31,686,000 as of its most recent SEC filing.

Several other hedge funds have also bought and sold shares of the stock. Tarbox Group Inc. boosted its stake in shares of Merck & Company by 0.5% in the third quarter. Tarbox Group Inc. now owns 3,133 shares of the company’s stock valued at $196,000 after buying an additional 16 shares during the last quarter. Lbmc Investment Advisors LLC boosted its stake in shares of Merck & Company by 0.6% in the third quarter. Lbmc Investment Advisors LLC now owns 3,730 shares of the company’s stock valued at $233,000 after buying an additional 23 shares during the last quarter. V Wealth Management LLC boosted its stake in shares of Merck & Company by 0.6% in the third quarter. V Wealth Management LLC now owns 5,353 shares of the company’s stock valued at $335,000 after buying an additional 34 shares during the last quarter. Bangor Savings Bank boosted its stake in shares of Merck & Company by 0.4% in the third quarter. Bangor Savings Bank now owns 10,116 shares of the company’s stock valued at $632,000 after buying an additional 39 shares during the last quarter. Finally, JFS Wealth Advisors LLC boosted its stake in shares of Merck & Company by 0.4% in the third quarter. JFS Wealth Advisors LLC now owns 10,349 shares of the company’s stock valued at $646,000 after buying an additional 40 shares during the last quarter. Institutional investors and hedge funds own 73.63% of the company’s stock.

Shares of Merck & Company, Inc. (NYSE:MRK) opened at 61.75 on Friday. The firm has a market cap of $170.25 billion, a price-to-earnings ratio of 31.54 and a beta of 0.77. The firm has a 50-day moving average price of $60.88 and a 200-day moving average price of $61.40. Merck & Company, Inc. has a 52-week low of $47.97 and a 52-week high of $65.46.

The firm also recently disclosed a quarterly dividend, which was paid on Monday, January 9th. Stockholders of record on Thursday, December 15th were given a $0.47 dividend. The ex-dividend date of this dividend was Tuesday, December 13th. This represents a $1.88 dividend on an annualized basis and a dividend yield of 3.04%. This is an increase from Merck & Company’s previous quarterly dividend of $0.46. Merck & Company’s payout ratio is currently 95.92%.

MRK has been the subject of several research reports. Vetr cut Merck & Company from a “buy” rating to a “hold” rating and set a $64.84 price target for the company. in a research report on Monday, October 10th. Barclays PLC reiterated an “overweight” rating on shares of Merck & Company in a research report on Wednesday, October 12th. Leerink Swann reiterated a “market perform” rating and set a $65.00 price target on shares of Merck & Company in a research report on Wednesday, October 12th. Bank of America Corporation upgraded Merck & Company from a “neutral” rating to a “buy” rating and boosted their price target for the stock from $57.00 to $70.00 in a research report on Thursday, October 13th. Finally, Zacks Investment Research upgraded Merck & Company from a “hold” rating to a “buy” rating and set a $70.00 price target for the company in a research report on Friday, October 14th. One research analyst has rated the stock with a sell rating, nine have issued a hold rating and thirteen have issued a buy rating to the company. The stock has an average rating of “Buy” and an average price target of $66.31.

In other Merck & Company news, Chairman Kenneth C. Frazier sold 140,000 shares of the business’s stock in a transaction dated Thursday, November 10th. The stock was sold at an average price of $65.03, for a total transaction of $9,104,200.00. Following the completion of the sale, the chairman now owns 514,957 shares of the company’s stock, valued at $33,487,653.71. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Rochelle B. Lazarus sold 20,000 shares of the business’s stock in a transaction dated Wednesday, November 2nd. The shares were sold at an average price of $59.06, for a total value of $1,181,200.00. Following the sale, the director now directly owns 9,594 shares of the company’s stock, valued at approximately $566,621.64. The disclosure for this sale can be found here. In the last ninety days, insiders sold 245,523 shares of company stock valued at $15,418,490. Company insiders own 0.05% of the company’s stock.

Merck & Company Company Profile

Merck & Co, Inc is a global healthcare company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products, which it markets directly and through its joint ventures. It operates through one segment, Pharmaceutical. The Company’s Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures.

Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Company, Inc. (NYSE:MRK).

Related posts

Leave a Comment